Prospect News: News for Serono SA

E-mail us: service@prospectnews.com Or call: 212 374 2800

Bank Loans - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products

Add to balance / Manage account

Not logged in

Prospect News home > Main news index > All issuers starting with S > All stories on Serono SA

Search again

Enter part or all of the issuer name:

Market:

All markets No structured products Bank loans Canadian bonds CLOs Convertibles Distressed debt Emerging markets High yield Investment grade Liability management Municipals PIPEs Preferreds Private placements All leveraged markets Structured products

Market: BK = Bank loans, CV = Convertibles, DD = Distressed Debt, EM = Emerging Markets, HY = High Yield, IG = Investment Grade, LM = Liability Management, MU = Municipals, PP = PIPEs, PF = Preferreds, PV = Private Placements, SP = Structured Products
Recent items, highlighted in orange, are $4.00 each. All others are $1.00 each. Headlines in gray are not currently covered by your subscription.

Serono SA

10/19/2006	BT	Serono retains Merrill's neutral rating
10/19/2006	BT	Serono reports strong third quarter, ends period with liquid assets of $2.1 billion
10/11/2006	BT	S&P: Pharmaceutical sales growth spurs mergers
9/25/2006	BT	Merrill cuts Serono to neutral
9/21/2006	BTCV	Moody's may downgrade Serono
9/21/2006	BT	Merck to acquire majority shares of Serono for CHF 16.6 billion
9/21/2006	BT	Market Commentary: Nycomed deal seen coming on Altana buy; Warner Chilcott slips on debut; Serono up on buyout
9/21/2006	BT	Serono's multiple sclerosis drug cladribine awarded fast-track status
9/18/2006	BT	Serono, Syntonix to collaborate on long-acting infertility treatment
9/14/2006	BT	Market Commentary: Threshold, Discovery Labs gain on widespread deal speculation; Curis better; Genzyme gains 3%
9/12/2006	BT	BioMarin, Serono release Phenoptin data in three clinical studies
9/7/2006	BT	Dyax, Serono enter agreement for antibody discovery
8/17/2006	BT	Serono's r-hGH for treatment of HARS shows positive results in phase 3 trial
8/4/2006	BT	Serono given buy rating by Merrill
7/27/2006	BT	Merrill retains Serono at buy
7/26/2006	BT	Serono reports 3.3% rise in second-quarter revenues to $699.2 million
7/10/2006	BT	Serono's Rebif gets approval for earlier use in multiple sclerosis
6/26/2006	BT	ZymoGenetics, Serono say results of TACI-Ig phase 1b trial in rheumatoid arthritis are promising
6/22/2006	BT	Serono says Raptiva provides 'significant' improvement in plaque psoriasis
5/4/2006	BT	Serono begins recruitment in phase 3 multiple sclerosis trial
4/21/2006	BT	Serono retained at buy by Merrill
4/20/2006	BT	Merrill keeps Serono at buy
4/10/2006	BT	Merrill keeps Serono at buy
4/10/2006	BT	Market Commentary: Cougar Biotech goes public via reverse merger, PIPE; Hythiam hammered; Serono sinks by 10%
4/10/2006	BT	Serono ends talks on selling company, calling bids too low
4/4/2006	BT	Serono submits new formulation of Rebif for multiple sclerosis
3/31/2006	BT	Serono's board seeks to issue more shares in effort to increase capital
3/15/2006	BT	BioMarin, Serono say all primary, secondary endpoints met in Phenoptin study
3/9/2006	BT	Serono stays at buy by Merrill
2/9/2006	BT	Market Commentary: Acorda IPO on deck with cheaper talk; Serono up on Glaxo chatter; Amylin soars; Charles River rises
2/6/2006	BT	Merrill rates Serono at buy
2/6/2006	BT	Market Commentary: OSI Pharma players debate new policy; Serono slips as 'for sale' sign stands; CuraGen gains 11%
1/24/2006	BT	Market Commentary: Nuvelo, Tercica toss hats in ring; Serono plunges on lack of suitors; Imclone results miss, seeks merger
1/24/2006	BT	Serono's Gonal-f approved in Japan for treatment of male hypogonadotropic hypogonadism
1/9/2006	BT	Serono's phase 3 trial of r-hGH to treat HIV-associated HARS meets primary, secondary endpoints
11/9/2005	BT	Market Commentary: CombinatoRx surges on debut; Angiotech off; Fisher issues soar; Digene slips on stock sale plans
11/9/2005	BT	Serono study shows MS patients taking Rebif can get flu vaccine
11/9/2005	BT	Jefferies maintains Serono at hold
11/9/2005	BT	Merrill retains Serono at buy
11/8/2005	BT	Market Commentary: Pharmaxis off on stock dilution; Patheon refinancing bank paper; Serono up on sale news
11/8/2005	BT	Serono retains Goldman Sachs to explore strategic alternatives
10/28/2005	BT	Jefferies lowers Serono's target to CHF 915
10/25/2005	BT	Merrill Lynch retains Serono at buy rating
10/25/2005	BT	Market Commentary: Indevus spikes on trial; Idenix off big on follow-on sale; Rigel up on Serono pact; Sepracor rises
10/17/2005	BT	Serono retains Merrill buy rating
10/17/2005	BT	Serono settles Serostim investigation
10/4/2005	BT	Serono held by Merrill Lynch at buy
10/4/2005	BT	Market Commentary: CancerVax crashes; Serono slips; Protein Design Labs cheered; Celgene off; Keryx up
9/27/2005	BT	Serono maintained by Jefferies at hold
9/13/2005	BT	Serono maintained by Merrill Lynch at buy
8/18/2005	BT	Serono stays at buy, Merrill says
7/20/2005	BT	Serono reiterated by Merrill Lynch at buy
7/13/2005	BT	S&P rates Serono A-
7/13/2005	BT	Serono may progress while Tysabri slows, Merrill bio/pharma earnings preview says
7/8/2005	BT	Market Commentary: BofA coverage boosts biotechs; Human Genome, other biodefense names mostly up; Transkaryotic firmer
6/29/2005	BT	Market Commentary: CV Therapeutics, Lonza upsize convertibles, both higher in trade; Millennium gains on new CEO
11/10/2003	CV	New Issue: Serono prices CHF600 million convertibles to yield 1.625%, up 53.8%

©2026 Prospect News. This page is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies, faxing, photocopying or any other form of reproduction.